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In asthma, excessive bronchial narrowing associated with thickening of the airway
smooth muscle (ASM) causes respiratory distress. Numerous pharmacological
agents prevent experimental airway hyperresponsiveness (AHR) when delivered
prophylactically. However, most fail to resolve this feature after disease is instated.
Although sphingosine analogs are primarily perceived as immune modulators with the
ability to prevent experimental asthma, they also influence processes associated with
tissue atrophy, supporting the hypothesis that they could interfere with mechanisms
sustaining pre-established AHR. We thus assessed the ability of a sphingosine
analog (AAL-R) to reverse AHR in a chronic model of asthma. We dissected the
pharmacological mechanism of this class of agents using the non-phosphorylatable
chiral isomer AAL-S and the pre-phosphorylated form of AAL-R (AFD-R) in vivo and in
human ASM cells. We found that a therapeutic course of AAL-R reversed experimental
AHR in the methacholine challenge test, which was not replicated by dexamethasone
or the non-phosphorylatable isomer AAL-S. AAL-R efficiently interfered with ASM cell
proliferation in vitro, supporting the concept that immunomodulation is not necessary
to interfere with cellular mechanisms sustaining AHR. Moreover, the sphingosine-1-
phosphate lyase inhibitor SM4 and the sphingosine-1-phosphate receptor antagonist
VPC23019 failed to inhibit proliferation, indicating that intracellular accumulation of
sphingosine-1-phosphate or interference with cell surface S1P1/S1P3 activation, are
not sufficient to induce cytostasis. Potent AAL-R-induced cytostasis specifically related
to its ability to induce intracellular AFD-R accumulation. Thus, a sphingosine analog that
possesses the ability to be phosphorylated in situ interferes with cellular mechanisms
that beget AHR.
Keywords: airway smooth muscle, sphingosine-1-phosphate, asthma, proliferation, airway hyperresponsiveness,
sphingosine analog
Abbreviations: AHR, airway hyperresponsiveness; ANOVA, analysis of variance; ASM, airway smooth muscle; HDM, house
dust mite (D. pteronyssinus); PP2A, protein phosphatase 2A; SEM, standard error of the mean; SIP, sphingosine-1-phosphate;
S1P1−5, S1P receptors 1 to 5; SphK2, sphingosine kinase 2.
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INTRODUCTION
Asthma is a prevalent and complex syndrome (Lotvall et al.,
2011). Alarmingly, a significant proportion of asthmatic patients
responds poorly to mainstay therapies, some achieving symptom
control only with oral prednisone; and others remaining
refractory to any pharmacological option currently available
(Reddel et al., 2015). There is thus a dire need for new therapeutic
options in asthma.
One of the distinctive features of asthma is AHR. Among the
multiple factors that interact to elicit AHR, the increased amount
of smooth muscle within the airway wall is thought to contribute
significantly. This paradigm is fuelled by several observations.
First, the amount of ASM is positively correlated with the
severity of asthma (James et al., 2009). Second, the capacity
to generate stress (force per cross-sectional area) is identical
between asthmatic and non-asthmatic ASM tissues (Ijpma et al.,
2015), implying that the amount rather that the stress-generating
capacity of ASM is involved in AHR. Third, airway narrowing
measured directly ex vivo is determined by the amount of ASM
(Noble et al., 2013). Strategies that aim at reducing the amount of
ASM should benefit asthmatic patients by reducing their level of
airway responsiveness. In this regard, bronchial thermoplasty, an
interventional procedure proven to reduce ASM volume (Salem
et al., 2016), decreases by nearly 50% the rate of exacerbations
in patients with moderate to severe persistent asthma (Wechsler
et al., 2013). However, there is currently no pharmacological
treatment that efficiently reverses ASM thickening.
Classically, sphingosine analogs like FTY720 and AAL-R
were recognized as S1P receptor modulators on the basis of
their propensity to be phosphorylated in vivo by SphK2, and to
induce S1P receptor-mediated events including lymphopenia
and bradycardia (Mandala et al., 2002; Sanna et al., 2004).
Yet, an emerging body of evidence now supports the concept
that sphingosine analogs may counteract mechanisms that
sustain or promote ASM thickening. For instance the non-
phosphorylatable sphingosine analog AAL-S reverses the
inhibition of PP2A (Figure 1) (Collison et al., 2013; Rahman
et al., 2016b) that occurs in allergic airways, which could
potentially interfere with proliferative cascades associated
with ASM cell expansion. Other evidence suggests that high
doses of the sphingosine analog FTY720 influence the levels of
ceramides (Oyeniran et al., 2015), which are potent inducers
of apoptosis and modulators of chronic inflammation. In
addition, intracellular S1P can cause autophagy (Liao et al.,
2012) and inhibit proliferation (Liao et al., 2007), which in
turn, could counteract ASM thickening (Stamatiou et al.,
2009). Importantly, in vitro data show that sphingosine
analogs can counteract cell amplification and/or survival via
SphK2-dependent intracellular accumulation of phosphorylated
sphingoid bases (Don et al., 2007; Jary et al., 2010). In agreement
with this growing body of evidence, we tested the concept
that this class of agents could reverse ASM thickening. We
show that the sphingosine analog AAL-R efficiently reverses
AHR and the underlying thickening of ASM. We unravel
the potential for this class of agents to act directly on ASM
cells and to induce cytostasis by a mechanism featuring
intracellular conversion of AAL-R to its phosphorylated
form.
MATERIALS AND METHODS
Murine Model and Experimental
Treatments
Pathogen-free BALB/c female mice (8 weeks old, Charles
River, Saint-Constant, QC, Canada) randomly assigned to
experimental groups were anesthetized with isoflurane and
instilled intranasally with 50µl of saline or with saline containing
50 µg of HDM extract (D. pteronyssinus; Greer, Lenoir, NC,
USA), three times a week, for 5 weeks. Mice were then left
untouched during week 6 (Figure 2). Sphingosine analogs
(AAL-S or AAL-R; see Gendron et al., 2015) or dexamethasone
(Sigma Aldrich, Oakville, ON, Canada) were injected i.p. at a
dose of 1 mg/kg once daily from day 7 to day 14 following
the last HDM instillation, and compared with a group receiving
an equal volume of the vehicle. Twenty-four hours following
the last injection, mice were anesthetized with ketamine-
xylazine and loss of toe-pinch reflex was verified. Mice were
then tracheotomised and connected to the flexiVent apparatus
(SCIREQ, Montreal, QC, Canada) to measure the level of
airway responsiveness to methacholine (OMEGA, Montreal, QC,
Canada) as described previously (Blanchet et al., 2007). To avoid
artifacts due to spontaneous respiratory muscle contractions,
mice were paralyzed with pancuronium (Sandoz, Boucherville,
QC, Canada). Heart rate was monitored until euthanasia in
order to ensure proper anesthesia. Bronchoalveolar lavage
fluid was harvested as described (Gendron et al., 2015) and
tissues were then fixed in phosphate buffered saline containing
4% paraformaldehyde for histological analyses. Experiments,
housing and care procedures were approved by the Committee
of Animal Care of Université Laval in accordance with the
guidelines of the Canadian Council on Animal Care (protocol
2013037).
Histological Analyses
Five micrometers-thick paraffin-embedded transverse lung slices
were stained with Masson’s trichrome for quantification of ASM
thickness. Using NDP View (Hamamatsu Photonics, Hamamatsu
City, Japan), the length of the basal membrane and the area
of ASM for individual circular bronchi was measured. ASM
thickness was defined as area of ASM divided by the length of
the basal membrane. Two to five bronchi were measured blindly
per lung and the average size of bronchi did not differ between
groups.
Cell Culture
Human primary ASM cells (CC-2576; Lonza, Walkersville,
MD, USA) were plated at a density of 104 cells per cm2
in Dulbecco’s Modified Eagle Medium containing 10% fetal
bovine serum (complete medium) for 24 h, and then incubated
with sphingosine analogs, the S1P lyase inhibitor (SM4; Zhao
et al., 2015) or the dual S1P receptor (S1P1−3) antagonist
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FIGURE 1 | Sphingosine analogs and their targets. AAL-R [(R)-2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol] and AAL-S
[(S)-2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol] are cell-permeant sphingosine analogs that readily penetrate into the intracellular space. Inside the cell, AAL-R
is rapidly phosphorylated by SphK2 into AFD-R [phosphorylated (R)-2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol]. Although not phosphorylatable, AAL-S still has
biological relevancy, such as positive regulatory effects on intracellular Protein Phosphatase 2A (PP2A) (Collison et al., 2013). The cell-impermeant molecule AFD-R
can either accumulate intracellularly to exert biological effects via unknown targets (Jary et al., 2010), or be transported into the extracellular space where it can
modulate cell surface S1P receptors.
FIGURE 2 | Experimental model. Mice received either saline or HDM three
times a week for 5 consecutive weeks. After 1 week of rest to allow acute
inflammation to resolve, mice were administered pharmacological treatments
daily for a period of 1 week and euthanized 24 h after the last dose for
analyses.
(VPC23019; Tocris, Burlington, ON, Canada) for 24–72 h. Cells
were either incubated with tetrazolium dye (MTT assay; 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma
Aldrich, Oakville, ON, Canada) to determine the viable
cell numbers; or incubated with bromodeoxyuridine (BrdU;
5-Bromo-2′-deoxyuridine; Roche, Laval, QC, Canada) overnight
to assess proliferation. Flow cytometric analyses were performed
as described (Gendron et al., 2015).
Quantification of Sphingolipids
Cell pellets were spiked with internal standards (C17-sphingosine
Cayman Chemical, Ann Arbor, MI, USA; C17-S1P, Avanti
Polar Lipids, Alabaster, AL, USA) and lipids were extracted
using a published method (Couttas et al., 2014). Liquid
chromatography tandem-mass spectrometry was performed at
PhenoSwitch Bioscience, Inc. (Sherbrooke, QC, Canada). Liquid
chromatography gradient was performed using 0.2% v/v formic
acid in water and with 0.2% v/v formic acid with 10 mM
ammonium formate in methanol on a reversed phase Halo
PFP column (Advance Materials Technology, Wilmington, DE,
USA), which was maintained at 50◦C. Acquisition was performed
with an ABSciex TripleTOF 5600 (Sciex, Foster City, CA, USA)
equipped with an electrospray interface. Quantification was done
using the area under the curve with the MuliQuant software
(Sciex). See Supplementary Methods and Supplementary Table 1
for details.
Statistics
Data were expressed using mean ± SEM. Homogeneity
of variance and normality of the data were verified.
When appropriate, variables were log-transformed. Rank
transformation and the ordinary F test from ANOVA were
used when appropriate. Data from mice were analyzed using
ANOVAs or two-way ANOVAs with an interaction effect.
When heteroscedasticity was significant, the statistical analyses
were performed using separate residual variance per group.
The Satterthwaite’s degree of freedom statement was added
for unequal variance structure. Posteriori comparisons were
performed using Tukey’s comparison. When appropriate,
bi-directional unpaired t-test was employed. The results were
considered significant with p-values ≤ 0.05. Data were analyzed
in collaboration with a professional biostatistician at the IUCPQ
biostatistics core service using the statistical package program
SAS v9.4 (RRID:SCR_008567; SAS Institute, Inc., Cary, NC,
USA).
RESULTS
AAL-R Reverses Airway
Hyperresponsiveness and Airway
Smooth Muscle Thickening
Using a model where persistent ASM thickening and AHR are
pre-established using chronic exposure to HDM (Figure 2),
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we first evaluated the in vivo potential of AAL-R to reverse
AHR, when administered at well-tolerated doses, yet sufficient to
induce biological effects. We found that AAL-R (1 mg/kg/day)
reversed HDM-induced AHR to a level 70% lower than the
vehicle treatment (Figure 3). Contrary to AAL-R, corticosteroid
intervention (dexamethasone; 1 mg/kg/day) failed to reverse
AHR, furthering the concept of usefulness for sphingosine
analogs in the context of asthma. On that note, we previously
showed that AAL-R efficiently interfered with the inflammatory
cascade in response to HDM soon after its instatement in the
airways (Gendron et al., 2015). In face of differing immune
mechanisms occurring in the remodeled airways (Mushaben
et al., 2013; Sordillo and Raby, 2014), and since alleviation
of eosinophilic inflammation can interfere with pathogenic
mechanisms of asthma, we also confirmed that AAL-R blunted
the antigen rechallenge-induced lymphocyte accumulation in
the bronchoalveolar lavage fluid, which was accompanied by a
profound 54% decrease of eosinophil numbers (Supplementary
Figure 1).
Since ASM thickening is central to the development of AHR,
we performed a new series of experiments where lungs of
mice receiving either AAL-R or vehicle after chronic HDM
exposure were stained with Masson’s trichrome, in order to
visualize the ASM layer located between the epithelium and
the parenchyma (Figure 4A). Mice receiving saline and vehicle
were used as baseline controls. Planimetry on transverse lung
slices revealed an average bronchial smooth muscle thickness of
4.1 ± 0.6 µm in the group receiving saline and vehicle. In the
group receiving HDM and vehicle, ASM thickness was increased
to 5.6± 0.5µm. This 36% increase in ASM thickness (Figure 4B)
was reduced to a near-baseline level of 4.3 ± 0.3 µm by AAL-R.
In agreement with reduced ASM thickness, AAL-R again robustly
reversed AHR caused by chronic exposure to HDM (not shown).
FIGURE 3 | AAL-R reverses airway hyperresponsiveness elicited by
chronic HDM exposure. Saline- or HDM- treated mice were administered
vehicle (VEH), AAL-R (1 mg/kg) or Dexamethasone (DEXA) (1 mg/kg) and the
degree of airway responsiveness was assessed by measuring the resistance
of the airway system (Rrs) in response to graded doses of methacholine.
n = 8 mice per group except DEXA where n = 6. “a” denotes a significant
difference vs. the SAL – VEH group, “b”: vs. HDM – VEH group, “c”: vs.
HDM – DEXA group. Significantly different at p < 0.05.
FIGURE 4 | AAL-R reverses ASM thickening. Mice received HDM or saline
(SAL) and underwent VEH or AAL-R treatment as described in Figure 2.
(A) Histological appearance of the airway wall. The smooth muscle layer is
delineated with a black dotted line. One representative image per group is
shown and the numbers represent the average thickness of the ASM
layer ± SEM. (B) The percentage of increase in ASM thickness relatively to
saline-VEH mice (baseline) was computed. Saline: n = 4; VEH: n = 7; AAL-R:
n = 7; ∗Significantly different at p < 0.05.
Thus, these three series of experiments revealed that AAL-R
retains its ability to inhibit TH2 inflammation in the remodeled
airways and efficiently reverses ASM thickening as well as the
ensuing AHR.
AAL-R Favors an Anti-proliferative
Balance in ASM Cells
Because AAL-R reverses AHR when administered at a phase
where acute inflammation is resolved, we next addressed the
idea that AAL-R could act directly on ASM cells to impair
underlying features of ASM thickening. We show that AAL-R,
but not its pre-phosphorylated/cell impermeant form (AFD-
R), nor its non-phosphorylatable isomer (AAL-S), efficiently
interfered with the proliferation of ASM. For instance, AAL-R
induced a 26% inhibition of bromodeoxyuridine incorporation
at 1 µM (Figure 5A), when compared to the vehicle. We then
set out to determine whether apoptosis also contributed to the
inhibition of ASM accumulation under mitogenic conditions. We
found that, at concentrations of 1 µM or lower, AAL-R mildly
modulated apoptosis in vitro (Figure 5B), while being a potent
cell death inducer at 10 µM with nearly 100% dead cells. On
the other hand, AFD-R failed to induce apoptosis, even at the
concentration of 10 µM (Figure 5B), and AAL-S only induced
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FIGURE 5 | AAL-R inhibits the proliferation of ASM cells. ASM cells were
incubated in complete medium with the indicated concentrations of AAL-R,
AAL-S, AFD-R or the vehicle (VEH; empty dot) for 72 h. (A) Proliferation was
assessed by bromodeoxyuridine incorporation. n = 4; ∗significantly different at
p < 0.05. (B) Annexin V binding was evaluated after 48 h of incubation.
Numbers show drug-induced increase in apoptosis (percentage over
vehicle-treated baseline). n = 6 except for VEH: n = 9 and AAL-R 10−6 M:
n = 8. ∗Shows statistical significance from VEH group at a p < 0.05. All
panels show representative results from two independent experiments.
partial apoptosis at 10 µM. Our results thus unravel a clear
potential for AAL-R to interfere with mechanisms that sustain
ASM cell proliferation.
FIGURE 6 | Endogenous sphingolipid modulation in response to
sphingolipid modifiers. ASM cells were incubated in complete medium.
When indicated, AAL-R (1 µM), AAL-S (1 µM), AFD-R (1 µM), SM4 (3 µM) or
the vehicle (VEH) were added for 24 h. Mass spectrometry was performed to
quantify S1P, sphingosine and ceramide in ASM cells. Shown is (A) the
S1P/sphingosine ratio and (B) C-16 ceramide. (C) Modulation of cell
accumulation in response to the experimental agents measured using the
tetrazolium dye assay. n = 6. ∗Shows statistically significant differences from
the VEH group at a p < 0.05.
Modulation of S1P Levels Does Not
Resolve the Potent Anti-proliferative
Effect of AAL-R
Given the putative impact of sphingosine analogs on the
balance of sphingolipidic species, we tested the concept that
intracellular S1P levels could explain the differential potency
of sphingosine analogs in inducing ASM cytostasis. We first
characterized which S1P pathway proteins were expressed
in ASM cells (Supplementary Figure 2). We detected the
expression of S1PR1 to S1PR3, both sphingosine kinases and S1P
lyase. In agreement with previously-documented sphingosine
and S1P levels in biological tissues, we found approximately
10 times more sphingosine than S1P in our ASM cultures
(Figure 6). AAL-R increased absolute levels of intracellular
S1P (2.0 ± 0.13 picomoles) when compared to the vehicle
(0.5 ± 0.05 picomoles), to AAL-S (0.6 ± 0.06 picomoles), and
to AFD-R (0.9 ± 0.05 picomoles). This resulted in a significant
twofold increase in the S1P/sphingosine balance, when compared
to the vehicle treatment (Figure 6A).
To resolve whether or not increase of intracellular S1P was
sufficient to induce cytostatis, cells were incubated with an
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FIGURE 7 | An S1P1/S1P3 antagonist does not induce cytostasis. ASM
cells were incubated in complete medium with the AAL-R (1 µM), AAL-S
(1 µM), AFD-R (1 µM), VPC23019 (at indicated concentrations) or the vehicle
(VEH) for 24 h and cell accumulation was assessed using the tetrazolium dye
assay. n = 8. ∗Shows statistically significant differences from the VEH-treated
group at a p < 0.05.
inhibitor of S1P lyase (Zhao et al., 2015) (Figure 6). The
S1P lyase inhibitor SM4 potently increased intracellular S1P
level (2.8 ± 0.08 picomoles), which resulted in a 33% increase
of the S1P/sphingosine ratio compared to the AAL-R-treated
cells (Figure 6A). This occurred in the absence of an effect
on the C16-ceramide content (Figure 6B). Also, we found no
evidence that AAL-R, AAL-S, or AFD-R (at the concentration
of 1 µM) impacted on cellular levels of C16-ceramide, arguing
against a major role for a shift in the sphingolipid rheostat to
justify AAL-R-induced cytostasis. In spite of potent enhancement
of intracellular S1P content, SM4 failed to inhibit ASM
cell proliferation (Figures 6A,C), revoking the sufficiency for
increased intracellular S1P content to induce ASM cell cytostasis.
Since intracellular accumulation of S1P might reduce
extracellular S1P levels and the subsequent impairment of S1P1-
and S1P3-proliferative effects, ASM cells were incubated with
the dual S1P1/3 antagonist (VPC23019; Figure 7). Similar to
AFD-R and AAL-S, dual inhibition of S1P1 and S1P3 failed to
significantly affect the accumulation of proliferating ASM cells
in vitro, when compared to the vehicle.
AAL-R Incubation Leads to Massive
Accumulation of Intracellular AFD-R in
ASM Cells
Since ASM cells express SphK2 (Supplementary Figure 2) and
because SphK2 activity is required for efficient phosphorylation
of AAL-R to AFD-R, we then addressed the hypothesis that AAL-
induced ASM cell cytostasis could be explained by intracellular
accumulation of AFD-R. Our results show that ASM cells uptake
AAL-R and AAL-S preferentially to AFD-R (Figure 8). This is
FIGURE 8 | AAL-R-induced cytostasis depends on intracellular
accumulation of AFD-R. ASM cells were incubated in complete medium.
When indicated, AAL-R (1 µM), AAL-S (1 µM), AFD-R (1 µM) or the vehicle
(VEH) were added for 24 h. Mass spectrometry was performed to quantify (A)
unphosphorylated total AAL species and (B) AFD-R. n = 6. ∗Shows
statistically significant differences from VEH group at a p < 0.05.
demonstrated by the retrieval of relatively high amounts of AAL
species in cells incubated with AAL-S (263 ± 17 picomoles)
and AAL-R (126 ± 15 picomoles), compared to an equimolar
concentration of AFD-R (32 ± 4 picomoles) (Figure 8A).
Most importantly, in ASM cells, the intracellular balance
between the non-phosphorylated and the phosphorylated form
of AAL-R favored the accumulation of AFD-R by up to
twofold (Figures 8A,B). Of note, this AFD-R accumulation
(263 ± 16 picomoles) represents more than 100 times
the cellular amount of S1P under the same experimental
conditions. Thus, ASM cells express SphK2 and display a massive
intracellular accumulation of AFD-R upon incubation with
AAL-R.
AAL-R but not AAL-S Efficiently
Reverses AHR
On the basis that efficient cytostasis of ASM cells relies on
in situ phosphorylation of the sphingosine analog, we ruled
out the ability of the non-phosphorylatable sphingosine analog
AAL-S to reverse AHR in our in vivo model. Figure 9 depicts
normoresponsiveness to graded methacholine doses in mice
receiving saline and vehicle. In this group, peak resistance
was recorded at 2.89 ± 0.27 cmH2O/ml/s in response to
an aerosolized dose of 30 mg/ml of methacholine. AHR was
present in the group receiving HDM and vehicle, with a
threefold increase of respiratory system resistance at 30 mg/ml
of methacholine, when compared to mice receiving saline and
vehicle. AAL-R again inhibited by more than 70% the HDM-
induced AHR at the methacholine dose of 30 mg/ml. In stark
contrast, the non-phosphorylatable AAL-S enantiomer failed to
alleviate AHR in HDM-exposed mice. Of note, neither AAL-R
nor AAL-S affected airway responsiveness to methacholine in
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FIGURE 9 | Reversal of airway hyperresponsiveness induced by
chronic HDM exposure requires a phosphorylatable sphingosine
analog. Mice received HDM or saline (SAL) and underwent AAL-R (1 mg/kg)
or AAL-S (1 mg/kg) treatment as described in Figure 2. The degree of airway
responsiveness was assessed by measuring the resistance of the airway
system (Rrs) in response to graded doses of methacholine. Saline: n = 11;
VEH: n = 15; AAL-R: n = 14; AAL-S: n = 6. “a” denotes a significant
difference vs. the SAL – VEH group, “b”: vs. HDM – VEH group, “c”: vs.
HDM – AAL-S group. Significantly different at p < 0.05.
mice without experimental asthma (Supplementary Figure 3A),
indicating that a 1 week-long exposure to either of these
two sphingosine analogs does not influence ASM contractility
per se. In agreement with the absence of AAL species-
induced alterations of lung histology (Supplementary Figure 3B),
these results confirm the lack of deleterious effects of these
compounds on pulmonary functions over a short period of
time.
DISCUSSION
This is the first evidence supporting sphingosine analogs
as proficient molecules to reverse ASM thickening after its
instatement, leading to a nearly full functional recovery of AHR
in the methacholine challenge test. We also deciphered that
immunomodulation is not required for AAL-R to induce a
catabolic response in ASM cells, as this effect occurs in vitro and
in absence of acute inflammation in vivo. Still, we also confirmed
that the short term AAL-R treatment remained efficient at
inhibiting inflammation in the remodeled airways in response
to repeated antigen challenges, and failed to induce aversive
functional alterations in the lung. We further confirmed that
mechanisms of action of this class of agents vary according to
their biochemical properties. More specifically, we defined that
the efficacy of sphingosine analogs to reverse ASM thickening
relied on the propensity to be phosphorylated in situ and
with the ability to increase intracellular AFD-R levels in ASM
cells.
We previously showed that a phosphorylatable sphingosine
analog could alleviate hyperreactivity in an acute model of
asthma where inflammation, but not remodeling, was pre-
established (Gendron et al., 2015). The beneficial effect, similar
to what is observed when sphingosine analogs are provided
prophylactically, likely resulted from the interference with
inflammation-associated release of pro-remodeling/spasmogenic
factors (Idzko et al., 2006; Marsolais et al., 2011; Karmouty-
Quintana et al., 2012; Collison et al., 2013). Yet in asthma,
remodeling is already present and its reversal remains a
preclinical challenge as supported by the work of Johnson et al.
(2008) showing that three interventions (corticosteroid, beta-2
agonist, and antigen weaning) are required to reverse AHR in
a chronic HDM-induced asthma model. These findings are in
line with the inability of a high dexamethasone dose (1 mg/kg) to
reverse AHR in spite of a significant alleviation of inflammation
(Mushaben et al., 2013). In agreement with the loss of efficacy of
prophylactic treatments once remodeling is established (Walters
et al., 2007; Mushaben et al., 2013), mechanisms that sustain
ASM thickening are likely to differ from the ones that initiate its
process.
In this regard, ASM cells found in a proliferative environment
become resistant to corticosteroid-mediated cytostasis (Stewart
et al., 1995; Dixon et al., 1999). In contradistinction, we
show a robust anti-proliferative effect of AAL-R occurring at
a concentration one order of magnitude lower than its pro-
apoptotic/cytotoxic effects. On these bases, it becomes tempting
to speculate that the preferential efficacy of AAL-R to inhibit
AHR, when compared with dexamethasone, relates to its potency
to induce cytostatic/catabolic effects in proliferating ASM cells.
This theory also agrees with our observation that the AAL isomer
that is not a potent cytostatic agent in vitro under mitogenic
conditions (AAL-S) fails to reverse AHR in vivo, despite its
documented anti-inflammatory effects (Collison et al., 2013;
Rahman et al., 2016b). Yet, the presumed absence of effect
of AAL-S on ASM thickening in our model remains to be
confirmed.
According to the pulmonary tropism of this class of
compounds (Meno-Tetang et al., 2006), concentrations of AAL-R
likely to induce cytostasis are attainable in the lung (Marsolais
et al., 2008), supporting a local effect of the sphingosine analog
on ASM cells, even when delivered systemically. One limitation
of this study is that we were not able to obtain in vivo
data on the impact of AAL-R on ASM cell proliferation or
apoptosis per se. While ASM cell proliferation or apoptosis
can be successfully assessed in larger mammals (Leung et al.,
2004; Ramos-Barbon et al., 2005; Hassan et al., 2010), their
assessment remains a challenge in mice due to the small
size of the airways, low nuclei count per bronchi, and rapid
elimination of apoptotic cells by phagocytes in vivo (Thorp,
2010). For these reasons, we can only conclude that the potency
of AAL-R to reverse AHR is linked with its propensity to
reverse ASM thickening in vivo and to induce ASM cytostasis
in vitro.
Current literature suggests that likely mechanisms
underlying the atrophic effects of sphingosine analogs include
activation of protein phosphatase 2A (Collison et al., 2013;
Rahman et al., 2016a), interference with sphingosine kinase
expression/activity (Tonelli et al., 2010), alteration of S1P
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receptor-driven pro-survival mechanisms (Fuerst et al., 2014)
and anti-proliferative/pro-apoptotic effects of intracellular
aminophosphate accumulation (Don et al., 2007; Liao et al.,
2007; Hagen et al., 2011). Our results support the last possibility.
Indeed, our results revoke the involvement of PP2A reactivation
in AAL-R-induced cytostasis since potent reduction of ASM
cell accumulation in vitro was not reproduced by the non-
phosphorylatable enantiomer AAL-S, a molecule shown to favor
PP2A activation in the context of asthma (Collison et al., 2013).
Yet, the possibility exists that AAL-S could inhibit inflammation,
when present, in the remodeled airways and by doing so,
alleviate AHR. This remains to be investigated. In regards to
inhibition of sphingosine kinases, both AAL-R and AAL-S can
interfere with sphingosine kinase activity (Don et al., 2007).
Yet, only AAL-R efficiently inhibited ASM proliferation in vitro
(Figure 5).
We observed increased intracellular S1P in cells treated with
AAL-R. This intracellular S1P likely resulted from interference
with S1P lyase activity and/or inhibition of S1P export
(Bandhuvula et al., 2005; Hisano et al., 2011). In T cells,
inhibition of proliferation was associated with intracellular S1P
acting through activation of nuclear S1P1 (Liao et al., 2007).
Alternatively, inhibition of S1P eﬄux is also likely to interfere
with a positive auto-feedback loop involving S1P receptors
(Liang et al., 2013), and might even contribute to counteract
pro-remodeling events occurring in response to S1P (Fuerst
et al., 2014). Still, the fact that neither the S1P lyase inhibitor
SM4, nor the S1P receptor antagonist VPC23019 modulated
proliferation of ASM cells argues against these possibilities
to explain AAL-R-induced cytostasis. Further studies will be
required to examine the intracellular pathways modulated by the
different sphingosine analogs. This type of study may provide
important insights as to why only AAL-R exerts a cytostatic
effect.
It remains possible that differential subcellular localization
of accumulating S1P between the current study and previous
studies (Liao et al., 2007; Hagen et al., 2009, 2011) might explain
the absence of effect of S1P lyase pharmacological inhibition on
proliferation. Still, quantification of phosphorylated sphingoid
bases in ASM cells show that the intracellular increase of S1P
is marginal compared to that of AFD-R in AAL-R-treated cells,
with a difference of at least two orders of magnitude in favor of
AFD-R. Moreover, the AAL-R-induced increase of intracellular
S1P appears to be much lower here than in models where it
induces cytotoxic effects (Hagen et al., 2009). Indeed, we found
only a threefold increase, while Hagen et al. (2009) showed that
S1P lyase genetic knock down caused a more than 100-fold
change of intracellular S1P. For these reasons it is more likely that
massive accumulation of AFD-R, rather than mild accumulation
of S1P, led to ASM cell cytostasis.
The fact that SphK2-metabolized sphingoid bases
preferentially interfere with cell accumulation also supports
the concept that, as described in Jurkat T cells (Don et al.,
2007), intracellular accumulation of AFD-R is the cause of ASM
cell cystostasis. For instance, AAL-R is mainly phosphorylated
by SphK2 and intracellular AFD-R accumulation is much
faster than the accumulation of other sphingosine analogs
(like FTY720). Importantly, this faster conversion relates to
the preferential ability of AAL-R to interfere with Jurkat T cell
accumulation in vitro, when compared with FTY720 (Jary et al.,
2010). In agreement with these observations, we determined
that ASM cells express SphK2 and display a nearly 2:1 AFD-R
to AAL-R ratio. In face of a preferential distribution of SphK2
at the endoplasmic reticulum (Maceyka et al., 2005) and since
accumulation of phosphorylated SphK2-derived sphingoid based
in that location can interfere with mechanisms that sustain
cell survival and promote proliferation through induction of
endoplasmic reticulum stress (Hagen et al., 2011; Wang et al.,
2015), we conclude that intracellular AFD-R accumulation is the
most likely event to explain interference with mechanisms that
sustain ASM thickening and the ensuing AHR. Our results do not
exclude the possibility that sphingosine analogs not investigated
in this study, such as FTY720, could also interfere with ASM cell
proliferation and thereby reverse AHR in experimental asthma.
However, current literature supports the theory that sphingosine
analogs displaying rapid rates of intracellular sphingoid bases
accumulation, like AAL-R, are more efficient to interfere with
cellular amplification than analogs featuring slower rates of
intracellular aminophosphate accumulation (Jary et al., 2010).
It is well-documented that a prolonged daily administration
of sphingosine analogs at low doses can increase the risk of
pulmonary side effects (Cohen et al., 2010), which likely relates
to the immunosuppressive activities of this class of agents. Over
a period of time that exceeds months, FTY720 might even be
associated with asthma exacerbations as exemplified by two case
studies (van Rossum et al., 2014; Zecca et al., 2014). Importantly,
such effect was never reported in clinical trials over a short period
of time. Nevertheless sphingosine analogs can become highly
potent cell death inducers at high concentrations, and potentially
harmful if administered at high doses during severe inflammatory
conditions (Shea et al., 2010). Still, short term treatments with
sphingosine analogs were repeatedly documented not to cause
pulmonary damage when administered locally in the airways
(Idzko et al., 2006; Marsolais et al., 2009; Gendron et al., 2015).
In the current study, we confirm the absence of aversive effects of
this type of agents in the airway. In fact, we document that AAL-
R remains efficient at inhibiting allergic airway inflammation in
the remodeled lung. Given the likely role of proinflammatory
mediators in the induction of tissue remodeling (Bates and
Maksym, 2011) and because numerous inflammation-derived
mediators can favor a spasmogenic response (Bosse, 2012), our
findings support the concept that AAL-R might tackle different
asthmatic phenotypes by acting on both airway remodeling and
inflammation.
CONCLUSION
We found that a punctual treatment with AAL-R resorbs the
thickening of ASM in the context of asthma, while not aversively
affecting the airways within a short time window. Moreover, we
determined that AAL-R could directly interfere with ASM cell
accumulation in vitro. This effect depends on the propensity of
this sphingosine analog to be phosphorylated in situ and likely
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results from an increase of the intracellular aminophosphate
content. Given the central role of ASM thickening in AHR and
asthma, this experimental therapeutic strategy needs to be further
explored.
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